Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-dimethylaminophenol (DMAP) is a small molecule aromatic compound containing both phenolic and amine functional groups. It is primarily used as an emergency antidote for acute cyanide poisoning and has also shown effectiveness in treating hydrogen sulfide toxicity. The mechanism of action involves the induction of methemoglobinemia; DMAP oxidizes hemoglobin to methemoglobin which binds cyanide ions and reduces their toxicity. This treatment is suitable only as an initial emergency intervention and must be followed by definitive therapy with agents such as sodium thiosulfate or cobalamin. Intravenous administration is preferred due to the risk of muscular necrosis with intramuscular injection[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-Dimethylaminophenol.